| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2014-09-11 | CTP-Modified Human Growth Hormone (MOD-4023) | growth hormone deficiency |
2 | OPKO Health (USA - FL) | Genetic diseases - Endocrine diseases - Hormonal diseases |
| 2014-09-09 | SM101 | systemic lupus erythematosus |
2a | SuppreMol (Germany) | Autoimmune diseases |
| 2014-09-09 | tregalizumab (BT-061) | active rheumatoid arthritis |
2b | Biotest (Germany) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
| 2014-09-09 | SER100 | systolic hypertension |
2a | Serodus (Norway) | Cardiovascular diseases |
| 2014-09-09 | SPI-2012 | neutropenia |
3 | Spectrum Pharmaceuticals (USA - NV) | Cancer - Oncology |
| 2014-09-09 | BioChaperone® Lispro U100 | type 1 diabetes |
2a | Adocia (France) | Metabolic diseases |
| 2014-09-08 | ESKAPE Pathogen Program including RX-P873 | preclinical | Melinta Therapeutics (USA - CT) | Infectious diseases | |
| 2014-09-08 | tiotropium | asthma |
3 | Boehringer Ingelheim (Germany) | Allergic diseases - Inflammatory diseases - Respiratory diseases |
| 2014-09-08 | Adempas® (riociguat) | chronic thromboembolic pulmonary hypertension (CTEPH) pulmonary arterial hypertension (PAH) |
Bayer Healthcare (Germany) | Rare diseases - Cardiovascular diseases - Respiratory diseases | |
| 2014-09-08 | benralizumab | chronic obstructive pulmonary disease (COPD) |
2a | AstraZeneca (UK) | Inflammatory diseases - Respiratory diseases |
| 2014-09-08 | lefamulin (BC 3781 - Acetic acid, 2-(((1R,2R,4R)-4-amino-2-hydroxycyclohexyl)thio)-, (3aS,4R,5S,6S,8R,9R,9aR,10R)-6-ethenyldecahydro-5-hydroxy-4,6,9,10-tetramethyl-1-oxo-3a,9-propano-3ah-cyclopentacycloocten-8-yl ester) | Nabriva Therapeutics (Austria) | Infectious diseases | ||
| 2014-09-08 | PLX-PAD Cells (Placental eXpanded cells) | pulmonary arterial hypertension (PAH) |
1 | Pluristem Therapeutics (Israel) United Therapeutics (USA - MD) | Rare diseases |
| 2014-09-08 | ThermoDox® (encapsulated doxorubicin) in combination with standardized radiofrequency ablation (sRFA) | hepatocellular carcinoma | 3 | Celsion (USA - NJ) | Cancer - Oncology |
| 2014-09-08 | drisapersen | Duchenne muscular dystrophy |
2 | Prosensa (The Netherlands) | Rare diseases - Neuromuscular diseases |
| 2014-09-07 | Ultibro® Breezhaler® (indacaterol/glycopyrronium bromide) | chronic obstructive pulmonary disease (COPD) |
Novartis (Switzerland) | Inflammatory diseases - Respiratory diseases | |
| 2014-09-07 | Afinitor® (everolimus) | pancreatic neuroendocrine tumors (pNET) |
3 | Novartis (Switzerland) | Cancer - Oncology |
| 2014-09-06 | flutiform® (fluticasone propionate and formoterol) | paediatric asthma |
3 | Skyepharma (UK) Mundipharma (UK) | Allergic diseases - Immunological diseases - Respiratory diseases |
| 2014-09-04 | inhaled Alpha-1 Antitrypsin (AAT) | alpha-1 antitrypsin deficiency (AATD, or Inherited Emphysema) |
2-3 | Kamada (Israel) | Genetic diseases - Rare diseases |
| 2014-09-04 | NOX-D19 (Spiegelmer® neutralizing the complement component C5a) | pneumococcal pneumonia-induced sepsis |
preclinical | Noxxon Pharma (Germany | Infectious diseases |
| 2014-09-04 | SBM-TFC-039 | type 2 diabetes |
preclinical | Sirona Biochem (Canada - France) Wanbang Biopharmaceuticals (China) | Metabolic diseases |
